West Pharmaceutical Services Inc
West Pharmaceutical Services Inc (WST) is listed on NYSE and classified in Medical Instruments & Supplies, part of the Healthcare sector. It is headquartered in Exton, United States and has 10,800 employees. The company is worth $27.73B and trades at 50.5x its earnings of the last twelve months; the median for its sector is 24.3x. Revenue was $3.07B in fiscal 2025, up 6.3% from the year before. Net income was $493.7M. The share price is within 3% of its 52-week high. It pays a dividend yielding 0.22%, and has raised its annual dividend for 28 years in a row in our records. 8 of the 38 superinvestors we track held it at the end of Q2 2026. The largest position belongs to Bill Gates (Gates Foundation Trust), at $159.58M. In that quarter, 3 of them opened or added to the position and 4 reduced it. No open-market insider trades in it were filed over the last 30 days.
Written from the data on this page: SEC filings (13F, Form 4, annual reports) and market prices.
Articles on this site that cover West Pharmaceutical Services Inc.
Year by year, from the annual reports; dividends from the payments themselves.
Bars are year-end balances; lines are what happened during the year.
Major managers that reported this stock in their latest 13F.
▼ -13.2% over 5Y.
today you would have $905.13▼ -9.5%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 18 closed years, each at that year’s closing price and reported numbers.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Year-end price | $275.14 | $327.56 | $352.12 | $235.35 | $469.01 | $283.31 | $150.33 | $98.03 | $98.67 | $84.83 | $60.22 | $53.24 | $49.06 | $27.38 | $18.98 | $20.60 | $19.60 | $18.89 |
Seven formulas applied to the reported numbers, each with its assumption next to the result. None of them predicts a price.
Square root of 22.5 × earnings × book value. Blind to intangibles, so it undervalues software and brands.
Earnings growing 8.2% a year plus a 0.2% dividend yield. Growth capped at 25%.
Median P/E of 24.3 among peers in the sector.
Median P/E of 38.1 across this company’s own years on record.
Cash flow growing 8.2% a year for 10 years, discounted at 10%, then 2.5% forever.
Sector median of 14.1x operating profit, less net debt. Banks have no EBITDA.
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| ROIVRoivant Sciences Ltd. | $37.45 | — | 6.4x | 0.00% | -8.52% | $27.05B |
| DGXQuest Diagnostics Inc | $243.28 | 25.8x | 3.6x | 1.41% | 14.60% | $26.85B |
| LHLabcorp Holdings Inc | $329.93 | 27.3x | 3.1x | 0.87% | 11.73% | $26.76B |
| PHGKoninklijke Philips NV | $26.92 |
| P/E | 38.1x | 40.5x | 49.0x | 44.7x | 30.4x | 54.1x | 62.0x | 46.8x | 35.8x | 49.6x | 44.4x | 46.3x | 30.4x | 31.2x | 23.8x | 17.6x | 21.8x | 18.5x | 15.1x |
| P/S | 4.2x | 6.4x | 8.2x | 8.7x | 6.0x | 12.3x | 9.8x | 6.0x | 4.2x | 4.6x | 4.1x | 3.1x | 2.7x | 2.5x | 1.5x | 1.1x | 1.2x | 1.2x | 1.3x |
| P/B | 5.4x | 6.2x | 8.8x | 9.0x | 6.5x | 14.9x | 11.3x | 7.1x | 5.2x | 5.7x | 5.5x | 4.3x | 4.0x | 3.8x | 2.6x | 2.0x | 2.2x | 2.2x | 2.8x |
| EPS | $6.79 | $6.69 | $7.88 | $7.73 | $8.67 | $4.57 | $3.21 | $2.74 | $1.99 | $1.91 | $1.30 | $1.75 | $1.57 | $1.15 | $1.08 | $0.95 | $1.06 | $1.25 |
| Dividend yield | 0.58% | 0.31% | 0.25% | 0.22% | 0.31% | 0.15% | 0.23% | 0.41% | 0.58% | 0.54% | 0.58% | 0.75% | 0.77% | 0.78% | 1.33% | 1.82% | 1.58% | 1.56% | 1.51% |
| Payout | 23.11% | 12.52% | 12.11% | 9.77% | 9.44% | 7.96% | 14.22% | 19.00% | 20.80% | 26.63% | 25.65% | 34.62% | 23.43% | 24.52% | 31.74% | 31.94% | 34.39% | 28.77% | 22.80% |
| Profit margin | 9.47% | 16.06% | 17.03% | 20.12% | 20.30% | 23.37% | 16.13% | 13.14% | 12.05% | 9.42% | 9.52% | 6.83% | 8.94% | 8.21% | 6.37% | 6.33% | 5.91% | 6.88% | 8.18% |
| ROE | 14.05% | 15.54% | 18.37% | 20.60% | 21.82% | 28.34% | 18.67% | 15.36% | 14.82% | 11.77% | 12.85% | 9.34% | 13.28% | 12.39% | 11.07% | 11.53% | 10.44% | 12.54% | 17.66% |
Median of the years shown; P/E years above 200x are left out.
The average of the method families that answered, not of the seven numbers: four of the seven start from the same earnings per share.
6 methods answered, across 3 families.
Room for errors in the reported numbers.
-61.1% from the average.
Models, not forecasts, and not investment advice. How each formula works →
| 20.1x |
| 2.0x |
| 3.75% |
| 10.15% |
| $26.31B |
| DXCMDexcom Inc | $78.32 | 31.8x | 11.3x | 0.00% | 38.49% | $29.55B |
| ALNYAlnylam Pharmaceuticals Inc | $227.28 | 37.9x | 22.4x | 0.00% | 96.56% | $30.41B |